In the United States, 1.4 million traumatic brain injuries (TBI) occur every year resulting in 235,000 hospitalizations and 50,000 deaths.
patients and are currently a level II recommendation (moderate degree of clinical certainty) from the Brain Trauma Foundation (BTF). 9 Despite these recommendations, there remains significant variability in practice of ICP monitoring. A survey of Canadian Neurosurgeons showed that although the majority use ICP monitoring in their patients, only 20.4% have a high level of confidence that routine monitoring improves outcomes in severe TBI. Nearly 80% felt that a prospective trial evaluating ICP monitoring is warranted. 10 Furthermore, a recent study demonstrated that although ICP monitoring was underutilized as per the BTF guidelines, it was associated with worsening of survival compared to the group who did not receive ICP monitoring. 11 The literature is further complicated by various types of ICP monitors used clinically. With the unreliability of subarachnoid and extradural locations, intra-parenchymal monitors and external ventricular drains (EVDs) are currently the most widely used. EVDs have the added benefit of draining cerebrospinal fluid, thus functioning as both monitor and therapy for elevated ICP.
Thus, the goals of this study are twofold: (1) to examine the adherence to BTF guidelines within our institution, a Canadian tertiary academic ICU and (2) examine the relationship between EVD use on 28-day and hospital mortality.
METHODS

Patient Inclusion & Data Collection
A retrospective cohort was constructed using the ICU database of all patients admitted to the ICU at Vancouver General Hospital with a severe TBI (Glasgow Coma Scale (GCS)<=8) between May 2000 and March 2006. Vancouver General Hospital is a 550 bed, tertiary care hospital affiliated with the University of British Columbia. The ICU is a closed, 27-bed, mixed medical-surgical unit, which operates with a 1:1 nurse to patient ratio, with resident and fellow staff in attendance. We excluded patients who were obeying commands within 12 hours, indicating a non-severe TBI. We further excluded those who died within 12 hours of ICU admission, as these patients were likely to succumb irrespective of EVD status. None of these patients died from complications related to EVD insertion. Patients were also excluded if they had a concomitant high cervical spine injury or obvious non-traumatic causes of their decreased level of consciousness (e.g. aneurysmal subarachnoid hemorrhage) identified during the chart review. All charts were reviewed and data collected using standardized forms. Data acquired included information on the type of injury, ICU management and monitoring information. Type and severity of injury was characterized by: best GCS in 12 hours, mechanism and type of TBI (diffuse axonal injury, parenchymal contusions, extra-axial collections, basal skull or calvarial fractures), surgical procedures performed and features suggestive increased ICP on CT scan on from radiology reports (mixed density lesion > 25mm, midline shift > 5mm, cisternal compression) and baseline vital signs. Traumatic brain injury management included use of bolus mannitol in ER (dose 1g/kg), cooling (target temperature and duration of therapy) and use of neuromuscular blockers. Monitoring data acquired included use of EVD, ICP measurements (if EVD present), use and values of jugular venous oximetry, and daily GCS. Demographic and outcome information, including 28-day and hospital mortality, were obtained from the ICU database. In addition, the ICU database contained the Acute Physiology and Chronic Health Evaluation (APACHE) II score, baseline admission laboratory values and vital signs for the first 24 hours.
Traumatic Brain Injury Management
Care of patients suffering TBI at our institution has been protocolized since 1995. All patients are maintained with: head of bed elevated above 30 degrees with their neck in a neutral position, mean arterial pressure >=70 mmHg (ensure adequate intravascular volume replacement with normal saline, and using norepinephrine infusion if required) and PaO 2 >= 70 mmHg. If ICP increases > 20 mmHg for greater than five minutes without stimulation, the EVD is opened to 26 cm H 2 O and cerebrospinal fluid is drained. Opened EVDs are closed every hour to measure ICP. Cerebral oxygen extraction ratio is maintained < 40% by ensuring adequate cerebral perfusion pressure, sedation and paralysis (if required), and careful titration of arterial CO 2 tension to modify cerebral blood flow. In addition, hyperthermia is avoided by using acetaminophen 650 mg every four hours and cooling blankets if required to keep the core temperature < 38 degrees. More aggressive cooling measures may be instituted on an individual basis to maintain ICP < 20 mmHg if the above maneuvers are insufficient.
Statistical Analysis
All analyses were performed with Stata 10.0 (StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP). Univariate analyses utilizing Fisher's exact testing for categorical data and independent t-tests for continuous data were used where appropriate. Wilcoxon ranksum tests were used for ordinal data, and non-normally distributed continuous data. All tests were two-sided and a pvalue < 0.05 was considered statistically significant.
Propensity Score & Logistic Regression Model
We used a multivariable logistic regression model to estimate the propensity of having an EVD inserted based on a large number of relevant covariates. Linearity in the log odds of continuous covariates was assessed visually, and by using likelihood ratio testing when constructing the propensity score. Covariates in the propensity score were selected based on their predictive ability to estimate insertion of an EVD (p < 0.2) and included: age, APACHE II score, increased ICP on computerized tomography scanning, administration of mannitol in the emergency room, year of admission, subdural hematoma, diffuse axonal injury, craniotomy performed, systolic blood pressure < 90 mmHg and arterial oxygen tension < 70 mmHg. Including these variables in the propensity score eliminates associations of all of the included variables with EVD insertion, and thus confounding by these covariates. The final c-statistic of the propensity score was 0.79.
We evaluated the association between EVD and 28-day and in-hospital mortality by using logistic regression models. These models included presence of EVD, GCS and the propensity score. We also assessed for effect measure modification of EVD on mortality by level of GCS by introducing an interaction term THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES into the model. We used the Likelihood ratio test to assess the significance of the interaction in the final model.
The protocol was approved by Clinical Research Ethics Board at the University of British Columbia and Vancouver General Hospital.
RESULTS
Reviewed and included in the analysis were 273 charts and 171 patients. (Figure 1 ). The baseline characteristics are presented in Table 1 . External ventricular drains were inserted in 98 patients. Patients in whom EVDs were inserted were younger, had lower best GCS within 12 hours, receive mannitol more frequently, were more likely to have a subdural hematoma or features suggestive of increased ICP on initial CT scan of the head, and undergo a craniotomy. Based on the current BTF guidelines for use of ICP monitors (GCS <=8 with an abnormality on CT scan), 63 of 73 patients in the non-EVD group would have qualified for ICP monitoring.
Outcomes by EVD status are presented in Table 2 . Hypothermia and jugular mixed venous oximetry were used more frequently in patients with EVDs. Patients with EVDs spent more time being mechanically ventilated and had a longer stay in the ICU. Patients with EVDs tended to have higher 28-day mortality (23% vs. 12%, p=0.07) and hospital mortality (29% vs. 12%, p < 0.01). The EVDs remained in situ for a median of eight days (SD six days).
In adjusted analyses, EVD use was associated with hospital mortality (OR 2.76, 95% CI: 1.07, 7.08, p=0.04) and 28-day mortality (OR 2.12, 95% CI: 0.80, 5.62, p=0.13), although the latter did not reach significance. Subgroup analysis demonstrated significant effect measure modification of EVD on mortality by level of GCS ( Figure 2 ) in a propensity score-adjusted model (p interaction =0.04). In other words, the risk of EVD on mortality differed by levels of GCS in the first 12 hours. In patients without an EVD, the probability of 28-day mortality decreased with increasing GCS. However, in patients with an EVD, the probability of 28-day mortality did not appear to change much with increasing GCS. As part of an exploratory analysis to quantify the differential effect of EVD on mortality, GCS was dichotomized to less than 6 versus 6 or greater based on the intersection of the probability distribution curves in Figure 2 . The adjusted results are presented in Table 3 . Test of interaction was repeated using the dichotomized GCS score and remained significant (p=0.01 for 28-day mortality and p=0.03 for hospital mortality). When GCS was less than 6, use of EVDs were not 
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DISCUSSION
In our study, EVD use was associated with a longer ICU length of stay and days of mechanical ventilation in patients with severe traumatic brain injuries admitted to the ICU. Propensity score-adjusted, multivariable regression modeling demonstrated that EVD use was associated with increased risk of hospital mortality (p=0.04) and 28-day mortality (p=0.13). However, this association was entirely driven by a substantially increased risk among patients with a GCS score of at least 6.
A recent retrospective study showed decreased survival associated with ICP monitoring; however, only 46% of the ICP monitors in their cohort were ventriculostomies. 11 As such, one of the main benefits of EVDs, drainage of CSF to treat intracranial hypertension, was not present in the majority of their cohort. Furthermore, the authors did not examine for effect modification of ICP monitoring by admission GCS. It's not surprising that the association of EVDs on mortality may depend on GCS. As patients with higher GCSs will tend to have less severe TBIs, the potential benefit to ICP monitoring may decrease. As expected, patients in our study with EVDs had more interventions aimed at reducing ICP, including sedation and neuromuscular blockade, which themselves increase morbidity in critically ill patients. 12, 13 Our results are in keeping with a recent observational study by Cremer and colleagues which demonstrated that compared to patients without ICP monitoring, those with ICP / CPP targeted therapy had longer duration of mechanical ventilation, and increased intensity of therapy as defined by increased use of sedatives, mannitol, vasopressors and barbiturates.
14 Thus, patients with less severe brain injuries would expect to benefit less from ICP monitoring, yet still be subjected to the therapies used to reduce ICP.
Another consideration is the duration of ICP monitoring. As patients improve and their ICPs normalize, the potential benefit of an EVD would diminish. The median length of EVD use in our cohort was eight days, with 44% of EVDs being in situ for ten or more days. A recent study of patients with severe TBIs by Stocchetti demonstrated a peak ICP in 80% of cases by Day 5, and 99% by Day 10. 15 Thus, very few patients would benefit from ICP monitoring for greater than ten days. After Day 6, the mean ICPs in our cohort were less than 16 mmHg, regardless if the EVD was removed that day or not. As such, the use of EVDs in less severely ill patients, or for a protracted period of time, may suffer the same limitations as the pulmonary artery catheter, which themselves have failed to improve outcomes in all but the most severely ill patients. [16] [17] [18] THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 46 Much like the pulmonary artery catheter, use of EVDs is subject to strong confounding by indication. In spite of wellrecognized guidelines, physicians will utilize ICP monitoring based on clinical judgment. As such, determining an unbiased estimate of the association of EVD with mortality is difficult, even if information on important confounders is available. We have made efforts to reduce confounding by restricting our cohort to have more comparable EVD and non-EVD groups. However, confounding by indication may still be present in our data, as patients receiving EVDs were younger, with a lower GCS, and more likely to have features of increased ICP on admission CT scan. This type of confounding was also observed in a recent cohort study from Austria, where ICP monitors were more likely to be inserted in younger patients, females and those with isolated TBIs. 19 In their study, patients with higher severity of illness, as measured by the Abbreviated Injury Scale of the head, were more likely to receive ICP monitoring. Increased intracranial pressure monitors were not associated with mortality, although they did not present outcomes by level of GCS, nor examine for interaction effects of ICP monitors by level of the Abbreviated Injury Scale or GCS. As with all observational data, unmeasured or residual confounding remains an alternative explanation for our findings. Additionally, in only considering mortality, we are not able to determine potential functional outcomes associated with EVD use in our population. Finally, generalizability is limited to ICUs with similar patient profiles and practice patterns as our own.
Strengths of our study include detailed clinical information from the chart using standardized data collection forms, uniform ICP monitor type, and use of propensity score-adjusted logistic regression modeling for control of confounding. Using this approach, we were able to control for a wide range of potential confounders. Propensity score adjusted models are less biased, more robust, and have greater power than traditional logistic regression when there are few outcome events. 20, 21 Within the strict guidelines of the BTF, EVDs were underutilized in our cohort. However, this may simply reflect the baseline differences between groups as mentioned previously. As such, it may be that clinicians are appropriately triaging the use of EVDs to those patients who are more severely ill. Although EVDs were associated with an increased 28-day and hospital mortality, this was only apparent in the subgroup of patients who had a better neurologic status in the first 12 hours (GCS >=6). Thus, further study to identify patients who may benefit from EVD use is warranted. In the meantime, given the association between intracranial hypertension and poor outcomes, 6, 7, 22 coupled with evidence demonstrating a high risk of intracranial hypertension with GCS ≤ 8 and an abnormal CT head, 8 it is difficult to recommend more restricted use of EVDs. However, clinicians should consider removing EVDs soon after the ICP begins to abate, and the patient can be followed clinically.
In conclusion, we have demonstrated that EVD use was associated with increased mortality; however, this was driven entirely by those patients with a best GCS ≥ 6. Further research is warranted to further refine which patients may benefit from ICP monitoring.
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